Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2016

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2016', provides in depth analysis on Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Overview 6

Therapeutics Development 7

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Products under Development by Stage of Development 7

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Products under Development by Therapy Area 8

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Products under Development by Indication 9

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Products Glance 10

Early Stage Products 10

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Products under Development by Companies 11

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Therapeutics Assessment 13

Assessment by Monotherapy/Combination Products 13

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 16

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Companies Involved in Therapeutics Development 17

Mateon Therapeutics Inc 17

Phelix Therapeutics, LLC 18

Virobay Inc. 19

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Drug Profiles 20

Drugs to Inhibit Cathepsin L for Infectious Diseases-Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

KGP-94-Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

VBY-129-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

VBY-285-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

VBY-825-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

VBY-X-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Dormant Projects 26

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Featured News & Press Releases 27

Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference 27

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 27

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 28

Appendix 30

Methodology 30

Coverage 30

Secondary Research 30

Primary Research 30

Expert Panel Validation 30

Contact Us 30

Disclaimer 31

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Actions, H2 2016 14

Number of Products by Stage and Routes of Administration, H2 2016 15

Number of Products by Stage and Molecule Type, H2 2016 16

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 13

Number of Products by Stage and Mechanism of Action, H2 2016 14

Number of Products by Stage and Route of Administration, H2 2016 15

Number of Products by Stage and Molecule Type, H2 2016 16

Pipeline by Mateon Therapeutics Inc, H2 2016 17

Pipeline by Phelix Therapeutics, LLC, H2 2016 18

Pipeline by Virobay Inc., H2 2016 19

Dormant Projects, H2 2016 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mateon Therapeutics Inc, Phelix Therapeutics, LLC, Virobay Inc.

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Therapeutic Products under Development, Key Players in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Therapeutics, Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Pipeline Overview, Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Pipeline, Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com